FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367834411> ?p ?o ?g. }

• W4367834411 endingPage "613" @default.
• W4367834411 startingPage "613" @default.
• W4367834411 abstract "Importance Current topical treatment options for seborrheic dermatitis are limited by efficacy and/or safety. Objective To assess safety and efficacy of roflumilast foam, 0.3%, in adult patients with seborrheic dermatitis affecting the scalp, face, and/or trunk. Design, Setting, and Participants This multicenter (24 sites in the US and Canada) phase 2a, parallel group, double-blind, vehicle-controlled clinical trial was conducted between November 12, 2019, and August 21, 2020. Participants were adult (aged ≥18 years) patients with a clinical diagnosis of seborrheic dermatitis for a 3-month or longer duration and Investigator Global Assessment (IGA) score of 3 or greater (at least moderate), affecting 20% or less body surface area, including scalp, face, trunk, and/or intertriginous areas. Data analysis was performed from September to October 2020. Interventions Once-daily roflumilast foam, 0.3% (n = 154), or vehicle foam (n = 72) for 8 weeks. Main Outcomes and Measures The main outcome was IGA success, defined as achievement of IGA score of clear or almost clear plus 2-grade improvement from baseline, at week 8. Secondary outcomes included IGA success at weeks 2 and 4; achievement of erythema score of 0 or 1 plus 2-grade improvement from baseline at weeks 2, 4, and 8; achievement of scaling score of 0 or 1 plus 2-grade improvement from baseline at weeks 2, 4, and 8; change in Worst Itch Numeric Rating Scale (WI-NRS) score from baseline; and WI-NRS success, defined as achievement of 4-point or greater WI-NRS score improvement in patients with baseline WI-NRS score of 4 or greater. Safety and tolerability were also assessed. Results A total of 226 patients (mean [SD] age, 44.9 [16.8] years; 116 men, 110 women) were randomized to roflumilast foam (n = 154) or vehicle foam (n = 72). At week 8, 104 (73.8%) roflumilast-treated patients achieved IGA success compared with 27 (40.9%) in the vehicle group ( P &amp;lt; .001). Roflumilast-treated patients had statistically significantly higher rates of IGA success vs vehicle at week 2, the first time point assessed. Mean (SD) reductions (improvements) on the WI-NRS at week 8 were 59.3% (52.5%) vs 36.6% (42.2%) in the roflumilast and vehicle groups, respectively ( P &amp;lt; .001). Roflumilast was well tolerated, with the rate of adverse events similar to that of the vehicle foam. Conclusions and Relevance The results from this phase 2a randomized clinical trial of once-daily roflumilast foam, 0.3%, demonstrated favorable efficacy, safety, and local tolerability in the treatment of erythema, scaling, and itch caused by seborrheic dermatitis, supporting further investigation as a nonsteroidal topical treatment. Trial Registration ClinicalTrials.gov Identifier: NCT04091646" @default.
• W4367834411 created "2023-05-04" @default.
• W4367834411 creator A5004423217 @default.
• W4367834411 creator A5009646867 @default.
• W4367834411 creator A5011094833 @default.
• W4367834411 creator A5013169089 @default.
• W4367834411 creator A5021906179 @default.
• W4367834411 creator A5022873173 @default.
• W4367834411 creator A5023573535 @default.
• W4367834411 creator A5025746305 @default.
• W4367834411 creator A5032745718 @default.
• W4367834411 creator A5045810816 @default.
• W4367834411 creator A5048521405 @default.
• W4367834411 creator A5052851982 @default.
• W4367834411 creator A5054928299 @default.
• W4367834411 creator A5056678869 @default.
• W4367834411 creator A5058903008 @default.
• W4367834411 creator A5060819284 @default.
• W4367834411 creator A5063690905 @default.
• W4367834411 creator A5066616903 @default.
• W4367834411 creator A5070890272 @default.
• W4367834411 creator A5078964682 @default.
• W4367834411 creator A5085051271 @default.
• W4367834411 creator A5089662030 @default.
• W4367834411 creator A5090367295 @default.
• W4367834411 creator A5091825921 @default.
• W4367834411 date "2023-06-01" @default.
• W4367834411 modified "2023-09-26" @default.
• W4367834411 title "Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis" @default.
• W4367834411 cites W2014928414 @default.
• W4367834411 cites W2037537994 @default.
• W4367834411 cites W2068416389 @default.
• W4367834411 cites W2103715242 @default.
• W4367834411 cites W2166611994 @default.
• W4367834411 cites W2284427833 @default.
• W4367834411 cites W2322560596 @default.
• W4367834411 cites W2469609569 @default.
• W4367834411 cites W273205602 @default.
• W4367834411 cites W2898684788 @default.
• W4367834411 cites W3003287697 @default.
• W4367834411 cites W3009944820 @default.
• W4367834411 cites W3025765757 @default.
• W4367834411 cites W3030572727 @default.
• W4367834411 cites W3042678059 @default.
• W4367834411 cites W3081663272 @default.
• W4367834411 cites W3090599855 @default.
• W4367834411 cites W3105761540 @default.
• W4367834411 cites W3138450947 @default.
• W4367834411 cites W4250535921 @default.
• W4367834411 cites W4253540737 @default.
• W4367834411 cites W4298379536 @default.
• W4367834411 cites W4379600190 @default.
• W4367834411 doi "https://doi.org/10.1001/jamadermatol.2023.0846" @default.
• W4367834411 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37133856" @default.
• W4367834411 hasPublicationYear "2023" @default.
• W4367834411 type Work @default.
• W4367834411 citedByCount "0" @default.
• W4367834411 crossrefType "journal-article" @default.
• W4367834411 hasAuthorship W4367834411A5004423217 @default.
• W4367834411 hasAuthorship W4367834411A5009646867 @default.
• W4367834411 hasAuthorship W4367834411A5011094833 @default.
• W4367834411 hasAuthorship W4367834411A5013169089 @default.
• W4367834411 hasAuthorship W4367834411A5021906179 @default.
• W4367834411 hasAuthorship W4367834411A5022873173 @default.
• W4367834411 hasAuthorship W4367834411A5023573535 @default.
• W4367834411 hasAuthorship W4367834411A5025746305 @default.
• W4367834411 hasAuthorship W4367834411A5032745718 @default.
• W4367834411 hasAuthorship W4367834411A5045810816 @default.
• W4367834411 hasAuthorship W4367834411A5048521405 @default.
• W4367834411 hasAuthorship W4367834411A5052851982 @default.
• W4367834411 hasAuthorship W4367834411A5054928299 @default.
• W4367834411 hasAuthorship W4367834411A5056678869 @default.
• W4367834411 hasAuthorship W4367834411A5058903008 @default.
• W4367834411 hasAuthorship W4367834411A5060819284 @default.
• W4367834411 hasAuthorship W4367834411A5063690905 @default.
• W4367834411 hasAuthorship W4367834411A5066616903 @default.
• W4367834411 hasAuthorship W4367834411A5070890272 @default.
• W4367834411 hasAuthorship W4367834411A5078964682 @default.
• W4367834411 hasAuthorship W4367834411A5085051271 @default.
• W4367834411 hasAuthorship W4367834411A5089662030 @default.
• W4367834411 hasAuthorship W4367834411A5090367295 @default.
• W4367834411 hasAuthorship W4367834411A5091825921 @default.
• W4367834411 hasBestOaLocation W43678344111 @default.
• W4367834411 hasConcept C118552586 @default.
• W4367834411 hasConcept C126322002 @default.
• W4367834411 hasConcept C141071460 @default.
• W4367834411 hasConcept C16005928 @default.
• W4367834411 hasConcept C1862650 @default.
• W4367834411 hasConcept C27415008 @default.
• W4367834411 hasConcept C2777484424 @default.
• W4367834411 hasConcept C2778515351 @default.
• W4367834411 hasConcept C2778715236 @default.
• W4367834411 hasConcept C2779121184 @default.
• W4367834411 hasConcept C535046627 @default.
• W4367834411 hasConcept C71924100 @default.
• W4367834411 hasConceptScore W4367834411C118552586 @default.
• W4367834411 hasConceptScore W4367834411C126322002 @default.
• W4367834411 hasConceptScore W4367834411C141071460 @default.

• next